Full Press Release Details
Media
• February 1, 2024
IRWD Positive Sentiment
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
Key Takeaway: Ironwood Pharmaceuticals has announced an upcoming investor update call scheduled for the fourth quarter and full year of 2023. This call aims to provide stakeholders with insights into the company's performance and future outlook. The event reflects Ironwood's commitment to maintaining open communication with its investors.
Price reaction · baseline $14.19 (2024-01-31 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close · peak
+2.9%
Market Sentiment Analysis
POSITIVE FACTORS
- Ironwood Pharmaceuticals is actively engaging with investors.
- The update call indicates transparency and communication.
- The event may provide insights into the company's performance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
When is the Ironwood investor update call scheduled?
The investor update call is scheduled for February 1, 2024.
What will be discussed in the investor update call?
The call will cover Ironwood's performance for the fourth quarter and full year of 2023.